Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

Original reporting
Published Nov 17, 2026, 12:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$FTH
Bullish
medium confidence
Mentioned
$FTH
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FTHBullishMed
01

Why it matters

The Roche collaboration and supply agreement provide a concrete next-step in testing PIKTOR with a next-generation endocrine backbone, supporting the thesis that the regimen can extend beyond paclitaxel-containing endometrial approaches.

02

Market read

Traders may reassess near-term risk/reward for FTH as the Roche partnership adds a tangible development pathway, even as the stock remains near lows after a steep recent decline.

03

What to watch

Key overhangs are regulatory execution and durability, and the article highlights the stock’s weak near-term momentum after a large selloff, which can cap upside until new trial data land.

Relevance 7/10Novelty 6/10Timing: today, post-announcement analyst reiterations and deal headline

Background

Faeth is developing PIKTOR (serabelisib plus sapanisertib) and is sponsoring Phase 1b/2 PIK-101; Roche supplies giredestrant (an oral SERD degrader) for a new HR+/HER2- combination trial.

Company-level read

Ticker impact

$FTHBullishMedium confidence
Context

Faeth (FTH) announced a Roche clinical-trial collaboration and supply agreement to test PIKTOR with giredestrant in HR+/HER2- advanced breast cancer.

Expected impact

Likely upward bias as investors price improved probability of regulatory execution and durability, despite recent sharp selloff.

Evidence & confidence

The article ties the Roche deal to a specific combination regimen and reiterates bullish analyst targets, while also noting the stock’s recent drawdown and near-52-week-low positioning.

Market effects

Reinforces investor appetite for targeted oncology combinations and endocrine backbone upgrades in HR+/HER2- breast cancer.

Limited, primarily affects US small/mid-cap biotech sentiment and the XBI complex.

Roche involvement may modestly lift cross-Atlantic biotech collaboration sentiment, but no broader market catalyst is indicated.

Counterpoint

The collaboration is an operational step, not a definitive efficacy or regulatory milestone, so the market may fade the initial optimism if trial endpoints or durability disappoint.

Key entities

  • Faeth Therapeutics

    NASDAQ-listed biotech developing PIKTOR; subject of the collaboration and analyst target reiterations.

  • Roche

    Supplies giredestrant and collaborates on the HR+/HER2- advanced breast cancer trial combination.

  • PIK-101

    Faeth-sponsored Phase 1b/2 trial evaluating PIKTOR in combination with giredestrant.

  • PIK-201

    Phase 2 trial in advanced endometrioid endometrial cancer with preliminary response and PFS figures cited in the article.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.